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Abstract Cancer therapy by endogenous or adoptively
transferred anti-tumor T cells is considered complementary
to conventional cancer treatment by surgery, radiotherapy
or chemotherapy. However, the scope of promising immu-
notherapeutic protocols is currently limited because tumors
can create a “hostile” immunosuppressive microenviron-
ment that prevents their destruction by anti-tumor T cells.
There is a possibility to develop better and more effective
immunotherapies by inactivating mechanisms that inhibit
anti-tumor T cells in the tumor microenvironment and
thereby protect cancerous tissues from immune damage.
This may be now possible because of the recent demon-
stration that genetic deletion of immunosuppressive A2A
and A2B adenosine receptors (A2AR and A2BR) or their
pharmacological inactivation can prevent the inhibition of
anti-tumor T cells by the hypoxic tumor microenvironment
and as a result facilitate full tumor rejection [Ohta A,
Gorelik E, Prasad SJ et al (2006) Proc Natl Acad Sci USA
103(35):13132–13137]. This approach is based on in vivo
genetic evidence that A2AR play a critical role in the
protection of normal tissues from overactive immune cells
in acutely inflamed and hypoxic areas. The observations of
much improved T-cell-mediated rejection of tumors in mice
with inactivated A2AR strongly suggest that A2AR also
protects hypoxic cancerous tissues and that A2AR should




Hypoxia-mediated protection of cancerous tissues
from anti-tumor T cells
The important role of T cells in cancer immunosurveillance
is now strongly supported by genetic studies in mice [1, 2]
and human studies [3–5]. The presence of T cells in solid
tumors is predictive of improved clinical outcome in some
cases of human colorectal cancer [3], esophageal carcinoma
[4] and ovarian cancer [5, 6]. Among recent advances in
cancer immunology are reports of relatively successful
adoptive T-cell therapy with selected forms of cancer [7]
and better designs of cancer vaccines and treatments that
improve the development of endogenous anti-tumor CD8
+
T-cell effectors [8–12].
However, the potential of T-cell-based immunotherapy is
limited by various immune escape mechanisms. The long
sought after explanation of the co-existence of tumors and of
anti-tumor immune cells in a patient (“Hellstrom Paradox”)
[13–15] or in a mouse [16] has been a challenging problem
to solve for more than 35 years. Why do anti-tumor T cells
fail to completely and reliably destroy tumors in vivo even
when the ability to recognize tumors is not the limiting
factor and when very high numbers of highly lytic anti-
tumor T cells are injected in a cancer patient [13, 15]o r
tumor-bearing mice [16]? What is it in the tumor microen-
vironment in vivo that prevents tumor destruction by the
tumor-specific and highly lytic in vitro anti-tumor CD8
+ T
cells?
Some of the failures of adoptive therapy could be due to
an inhibition of anti-tumor T cells by “passenger” T
suppressor cells [17] and/or by cytokines, which inhibit
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addition, convincing data from clinical and animal studies
have shown that the tumor microenvironment itself can
suppress anti-tumor T cells [13]. Although substantial
progress has been made in studying tumor escape from
anti-tumor immune response [19], the mechanism of
inhibition of lethal anti-tumor Tcells in a poorly understood
“hostile” tumor microenvironment [13–16] is still perplex-
ing. The importance of dealing with these issues and
eliminating negative effects of the tumor microenvironment
on cancer therapies is well recognized, as reflected in
current extensive studies [20]. The puzzling inhibition of
anti-tumor T cells in the tumor microenvironment provides
yet another challenge [13, 15, 16].
Important clues to further understanding cancerous tissue
protection from anti-tumor T cells have been provided by
our recent insights into mechanisms of normal tissue
protection from overactive immune cells [1]. We found
that the still healthy normal tissues in acutely inflamed and
therefore hypoxic areas under immune attack are protected
from the continuing collateral immune damage by immu-
nosuppressive signaling through extracellular A2 receptor
[21–25] on the surface of immune cells.
Delayed negative feedback mechanism of protection
of normal tissues from overactive immune cells
by extracellular adenosine A2 receptors on the
surface of immune cells
The A2 receptor-mediated mechanism of normal tissue
protection from overactive immune cells in inflamed areas
may be triggered by excessive collateral immune damage to
endothelial cells and microcirculation with ensuing inter-
ruption of normal blood and oxygen supply [23]. In turn,
this results in local tissue hypoxia [23, 24]. The hypoxia is
associated with: (1) decrease in intracellular ATP [26]; (2)
increase in intracellular AMP [26]; (3) inhibition of
adenosine kinase [27]; (4) activation of 5′-nucleotidase
[26, 28]; (5) accumulation of intracellular adenosine [26,
27]; (6) subsequent transport or diffusion of adenosine from
the cell into extracellular space [26].
The sufficiently high levels of extracellular adenosine
trigger signaling by A2A receptors (A2AR) and/or A2B
receptors (A2BR) on the surface of surrounding cells
including activated T cells. This chain of events culminates
in inhibition of overactive immune cells in a delayed
negative feedback manner [22–25] due to the well-
Fig. 1 Model of hypoxia-
mediated adenosine protection
of tumors from T cells
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[22–34] (Fig. 1).
Immunosuppression by extracellular A2AR and A2BR
on immune cells
There are four different and widely distributed adenosine
receptors: A1, A2A, A2B, and A3 [35, 36]. The high-
affinity A1 receptor and low-affinity A3 receptor are
Gi-proteincoupled.ThecAMP-elevatingGs-proteincoupled
A2 receptors are subdivided into high-affinity A2AR and
low-affinity A2BR. Adenosine receptors are known to be
immunosuppressive (reviewed in [23, 24, 36]). The CD8
+ T
cells, including anti-tumor CD8
+ T cells and human T cells,
predominantly express A2AR and A2BR and not the A3
receptor [29, 31, 37]. The cAMP-elevating signaling
through A2AR or A2BR in T cells results in inhibition of
TCR-triggered activation of T cells [32–34, 38] and of
many effector functions, including proliferation, expansion
and secretion by T cells of such important anti-tumor
cytokines as IFN-g [29, 39, 40] and TNF-a [41]. In contrast
to our focus on A2AR and A2BR as the key immunosup-
pressive molecules in T cells, others have suggested instead
the A3 adenosine receptors [42].
Tumor hypoxia and extracellular adenosine
Many solid tumors are characterized by an insufficient
oxygen supply and transient or chronic hypoxia in some
microenvironments [43, 44]. Tumor hypoxia may contrib-
ute to the propagation of oncogenic signals in the tumor
microenvironment as was shown in demonstration of the
switch to the angiogenic phenotype [45]. As a result, tumor
hypoxia is associated with poor prognosis for the patient
[46, 47].
Remarkable progress has been made in measuring and
discriminating effects of moderate versus deep tumor
hypoxia [46, 48]. New conceptual and methodological
approaches in the area of cancer research offer novel
opportunities for other studies far beyond cancer research.
Indeed, an interrupted blood supply and transient or chronic
hypoxia in some microenvironments are observed not only
in cancerous tissues [43, 44, 46–48], but also in inflamed
normal tissues [49, 53]. The hypoxia-associated accumula-
tion of intracellular adenosine [26] in tumors and subse-
quent transport or diffusion of adenosine from the cell into
extracellular space is one of the important mechanisms of
extracellular adenosine accumulation in the tumor micro-
environment [50].
It is important to emphasize that many normal tissue
microenvironments are hypoxic to start with (reviewed in
[23, 24]). Therefore, individual cancerous cells in newly-
arising, small tumors in such anoxic “shelters” may be
protected from T cells by the hypoxia-produced adenosine,
but in this case it will not be the “tumor-hypoxia produced
adenosine” but the “tissue microenvironment-produced
adenosine”, which then will be helped by contributions
from adenosine produced by tumor tissues themselves.
It was important to establish whether genetic deletion or
pharmacological inactivation of A2AR and/or A2BR by
drugs will make anti-tumor T cells more resistant to
inhibition in the tumor microenvironment and thereby
facilitate tumor destruction [1]. If that was the case, then
the translation into clinical settings could be unusually
immediate due to the well-established safety profiles and
known limitations of available A2AR/A2BR antagonists,
including 1,3,7-trimethylxanthine (caffeine).
Genetic and pharmacological in vitro and in vivo
evidence shows that: (1) anti-tumor CD8
+ T cells do express
inhibitory A2AR and A2BR; (2) solid tumors are sur-
rounded by extracellular adenosine; (3) A2 adenosine
receptors are capable of inhibiting anti-tumor T cells in
vitro; (4) most importantly, dramatic and complete rejection
of tumors in mice is accomplished by genetic A2AR
inactivation [1], providing the strongest evidence for the
function of this mechanism in protection of cancerous
tissues from anti-tumor CD8
+ T cells in vivo; (5) T cells
may be made much more resistant to inhibition in the
tumor microenvironment by pharmacologically targeting
the A2 receptors in vivo and this is reflected in
observations of significant tumor growth retardation due
to antagonism of A2AR and A2BR by drugs, including an
A2 receptor antagonist caffeine; (6) better tumor rejection
observed in A2 receptor antagonist-treated mice is at least
partially explained by stronger inhibition of pro-tumor
neo-vascularization due to an increased IFN-g production
by “de-inhibited” anti-tumor CD8
+ T cells in the tumor
microenvironment [1].
Importantly, the deficiency in A2AR did not prevent the
establishment or the early growth of small inoculated
tumors; rather, it improved the destruction of well-
established tumors after the host has developed anti-
CL8-1 or anti-RMA CD8
+ T cells [1]. Observations of
complete rejection of established melanoma and solid T
lymphoma tumors in ~60% of A2AR
-/- mice with no tumors
rejected in A2AR
+/+ controls indicated that A2AR do play
an important role in the mechanism of tumor protection
from immune cells [1].
Interestingly, the CD8
+ T-cell-mediated anti-CL8-1
melanoma response in the A2AR
-/- host was accompanied
by a different appearance of tumors and of tumor-rejecting
mice compared with the tumor-permissive A2AR-
expressing wild-type control mice. While the solid, spheri-
cal, and well-definedtumors were continuously increasing in
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A2AR
-/- mice often showed central necrosis, and their
disappearance and healing were, in some mice, accompa-
nied by hair loss [1]. These signs of spontaneously resolved
autoimmunity resemble autoimmunity in vaccinated mela-
noma-rejecting mice [51] and in melanoma patients under-
going immunotherapy with melanoma antigen-specific T
cells [52]. These observations provide yet more strong
evidence that inactivating the adenosine-A2AR/A2BR
pathway did facilitate effector functions of anti-tumor T
cells.
Also demonstrated was the feasibility of the pharmaco-
logical anti-adenosinergic strategy in several tumor rejec-
tion assays by endogenously developed and adoptively
transferred T cells. The treatment with antagonists of A2
receptors significantly delayed the onset of rapid growth of
CL8-1 melanoma, even if injections of antagonists
ZM241385 or caffeine started after tumors reached 8 mm
in diameter size [1].
Inhibition of tumor neovascularization by interruption
of tumor-protection by the “hypoxia-adenosine-A2R”
pathway
As it was shown, the dramatic inhibition of tumor neo-
vascularization can be achieved by A2 receptor antagonists
[1]. These data suggest that the improvement of tumor
destruction by interruption of A2 receptor signaling could be
due to the release of CD8
+ T cells from A2R-mediated inhi-
bition of IFN-g production and subsequent IFN-g -mediated
inhibitionofpro-tumorangiogenesis[1]. These observations
are in agreement with recent findings that the angiogenesis-
inhibiting properties of T-cell-produced IFN-g are important
for anti-tumor action of T cells in vivo [39].
The genetic and pharmacological data described above
are interpreted both as: (1) evidence for the role of a tumor
hypoxia-adenosine-A2A/A2B receptor pathway in the
physiological mechanism of cancerous tissue protection
from anti-tumor T cells, and (2) promising proof of
principle for future investigations of this strategy to
enhance the immune-mediated tumor destruction by genetic
targeting of A2AR and A2BR, or by combined inactivation
of both A2 receptors.
The described retardation of tumor growth by A2A
antagonists was observed even under conditions unfavor-
able for tumor rejection because the used drugs are
“competitive” antagonists and at levels found in vivo they
are expected to prevent inhibitory signaling of only ~30%
of A2AR [1]. Moreover, such incomplete inhibition of
A2AR by antagonists would be lasting no more than 30%
of time due to short half-life of antagonists in vivo. This
explains incomplete tumor rejection by drugs compared
with genetic inactivation of A2AR, which accomplishes
100% deletion of receptors for 100% of the time [1]. In
view of these considerations, the retardation of tumor
growth by even inferior drugs bodes well for stronger
anti-tumor effects of better and longer-lived antagonists.
Limitations of genetic targeting of A2AR alone
The described approach resulted so far in complete tumor
rejection in only ~60% of mice with genetically targeted
A2AR [1]. The tumor’s escape from CD8
+ T cells that was
observed in ~40% of A2AR
-/- mice was not due to the loss
of antigen-presenting molecules, but could be explained by
the expression of inhibitory, lower affinity A2BR on
A2AR
-/- CD8
+ T cells. While A2AR/A2BR antagonists
ZM241385 and caffeine are capable to significantly delay
tumor growth by relieving anti-tumor CD8
+ T cells from
inhibition, these drugs did not accomplish the complete
rejection of immunogenic tumor [1]. Therefore, it is very
important to further improve the therapeutic window. If the
failure of tested antagonists to completely reject tumors are
due to their short half-life, then the most straightforward
alternative approach would be to use the longer-lived
antagonists.
Conclusion
Despite strong evidence that the adenosine-A2A adenosine
receptor pathway in T cells represent important novel target
for improving cancer immunotherapy, the role of A2BR on
T cells is not yet fully identified. It is up to future studies to
find whether A2BR also may account for the failure of
CD8
+ T cells to destroy tumors in ~40% of A2AR
-/- mice.
Most importantly, the data described above strongly suggest
the need to attempt the complete rejection of tumors by
adoptively transferred or endogenous anti-tumor T cells by
targeting both A2AR and A2BR.
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